Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 13/20 | 0.38 |
| ▸ | ESR1 | P03372 | 11/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 3/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20850537 | 0.82 | CDK2 (0.43) | ESR2ESR1IDO1CDK2FLT3 | |
| SCHEMBL21986879 | 0.77 | NOS1 (0.42) | ESR2ESR1IDO1CDK2FLT3 | |
| SCHEMBL21986864 | 0.77 | IDO1 (0.40) | ESR2ESR1IDO1CDK2CCNA1 | |
| SCHEMBL25791157 | 0.74 | AKT2 (0.43) | IDO1CDK2FLT3CCNA1NOS1 | |
| SCHEMBL8404436 | 0.70 | IDO1 (0.46) | ESR2ESR1IDO1CDK2FLT3 | |
| SCHEMBL21250571 | 0.70 | PDPK1 (0.37) | CDK2FLT3 | |
| SCHEMBL21986783 | 0.70 | IDO1 (0.37) | ESR2ESR1IDO1CDK2FLT3 | |
| SCHEMBL22864052 | 0.69 | JAK2 (0.38) | ESR2ESR1IDO1CDK2FLT3 | |
| SCHEMBL25808844 | 0.68 | ESR1 (0.41) | ESR2ESR1IDO1CDK2FLT3 | |
| SCHEMBL21938210 | 0.68 | IDO1 (0.38) | ESR2ESR1IDO1CDK2FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230147053-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20200385364-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2020-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230147053-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | ESR2 1546/4885ESR1 522/4885IDO1 4717/4885 |
| US-20200385364-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | ESR2 1209/4885ESR1 374/4885IDO1 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.